Abstract:Background: Amyloid-beta (Abeta)-directed antibodies tested clinically for therapeutic activity against Alzheimer disease (AD) have shown varying degrees of efficacy. Although all of these antibodies target the Abeta peptide, their binding profile to different molecular species of Abeta differs and may underlie the observed variability in clinical outcomes. Objective: Explore the relationship between targeting of soluble toxic Abeta species and therapeutic efficacy. Methods: Surface plasmon resonance (SPR) was used to conduct a side-by-side comparison of the binding of various Abeta-directed antibodies to monomers and soluble Abeta oligomers from AD brains. Immunohistochemistry was performed to assess reactivity with plaque. Preclinical activity was assessed in human amyloid precursor protein (APP) transgenic mouse models of AD. Results: Non-selective, pan-Abeta reactive antibodies such as crenezumab and gantenerumab, which have failed to produce a clinical benefit, bound all forms of Abeta tested. In a competition assay, these antibodies lost the ability to bind toxic AD brain oligomers when exposed to monomers. Aggregate-selective antibodies such as aducanumab, lecanemab and donanemab, showed reduced monomer binding and a greater ability to withstand monomer competition which correlated with their reported inhibition of cognitive decline. Of the antibodies in earlier stages of clinical testing, ACU193 and PMN310 displayed the greatest ability to retain binding to toxic AD brain oligomers while PRX h2731 was highly susceptible to monomer competition. Plaque binding was observed with all aggregate-reactive antibodies with the exception of PMN310, which was strictly selective for soluble oligomers. Targeting of oligomers by PMN310 protected cognition and was not associated with microhemorrhages in mouse models of AD. Conclusions: Overall, these results suggest that selectivity for soluble toxic Abeta oligomers may be a driver of clinical efficacy, with a potentially reduced risk of ARIA if engagement with plaque is minimized.

Conformation-dependent single-chain variable fragment antibodies specifically recognize beta-amyloid oligomers.

Conformation-dependent scFv antibodies specifically recognize the oligomers assembled from various amyloids and show colocalization of amyloid fibrils with oligomers in patients with amyloidoses

Mechanism Exploration of Amyloid-β-42 Disaggregation by Single-Chain Variable Fragments of Alzheimer's Disease Therapeutic Antibodies.

Mechanism Exploration of Amyloid-β-42 Disaggregation by Single-Chain Variable Fragments of Alzheimer’s Disease Therapeutic Antibodies

Inhibitor discovery targeting the intermediate structure of beta-amyloid peptide on the conformational transition pathway: implications in the aggregation mechanism of beta-amyloid peptide.

Inhibitor discovery targeting the intermediate structure of β-amyloid peptide on the conformational transition pathway: Implications in the aggregation mechanism of β-amyloid peptide

An Enzyme-Linked Immunosorbent Assay To Compare The Affinity Of Chemical Compounds For Beta-Amyloid Peptide As A Monomer

Advances in targeted tracking and detection of soluble amyloid-β aggregates as a biomarker of Alzheimer's disease

An enzyme-linked immunosorbent assay to compare the affinity of chemical compounds for β-amyloid peptide as a monomer

Molecular Recognition between Aβ-Specific Single-Domain Antibody and Aβ Misfolded Aggregates

Fc Effector of Anti-Aβ Antibody Induces Synapse Loss and Cognitive Deficits in Alzheimer’s Disease-Like Mouse Model

Human Anti-Beta-Amyloid Antibodies Block Beta-Amyloid Fibril Formation and Prevent Beta-Amyloid-Induced Neurotoxicity

Molecular Recognition Between A-Specific Single-Domain Antibody And A Misfolded Aggregates

Relationship between therapeutic activity and preferential targeting of toxic soluble aggregates by amyloid-beta-directed antibodies

Computational Investigation of Gantenerumab and Crenezumab Recognition of Aβ Fibrils in Alzheimer's Disease Brain Tissue.

Epitope Mapping by NMR of a Novel Anti-Aβ Antibody (STAB-MAb)

Application of engineered antibodies (scFvs and nanobodies) targeting pathological protein aggregates in Alzheimer's disease

Effects of a Multimerized Recombinant Autoantibody Against Amyloid-β

Single-molecule characterisation of soluble beta-amyloid aggregate binding by Aducanumab, Lecanemab, Gantenerumab, and Donanemab

Impact of Alternating Amino Acid Sequences on Beta-Amyloid-induced Neurotoxicity and Neuroinflammation in Alzheimer's Disease.

Assembly of Nanoconjugates as New Kind Inhibitor of the Aggregation of Amyloid Peptides Associated with Alzheimer's Disease